Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.

Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page
- Check5 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check13 days agoChange DetectedUpdates to the study record dates show new entries on 2026-03-02, 2026-02-26, and 2026-02 and removal of entries on 2025-12-24, 2025-12-08, and 2025-12, indicating revisions to the trial information.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedFooter and navigation updates removed references to the Moffitt Cancer Center Clinical Trials website and the H. Lee Moffitt Cancer Center and Research Institute. A new Revision: v3.4.2 tag was added.SummaryDifference0.6%

- Check41 days agoChange DetectedA government funding notice was added and the revision stamp updated to v3.4.1 (replacing the previous v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check48 days agoChange DetectedAdded a Show glossary option and new/updated metadata fields (Last Update Submitted that Met QC Criteria and Last Update Posted) with a footer Revision: v3.4.0. Removed or revised items include No FEAR Act data and Revision: v3.3.4.SummaryDifference0.3%

- Check62 days agoChange DetectedFooter revision label updated to v3.3.4, replacing v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.